PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan

Int J Clin Oncol. 2024 Jul;29(7):863-864. doi: 10.1007/s10147-024-02531-1.

Noriomi Matsumura^{1

2}, Masaki Mandai^{3

4}

¹ Faculty of Medicine, Kindai University, Osaka-Sayama, Japan. noriomi@med.kindai.ac.jp.
² Editorial Committee, Japan Society of Clinical Oncology, Tokyo, Japan. noriomi@med.kindai.ac.jp.
³ Editorial Committee, Japan Society of Clinical Oncology, Tokyo, Japan.
⁴ Kyoto University Graduate School of Medicine, Kyoto, Japan.

No abstract available

Publication types